The Health and Community Services (HCS) in Jersey will investigate the deaths of 182 rheumatology patients following a critical independent review of the service, which treats individuals with arthritis and related conditions.
The information disclosed that 2,400 living patients were reviewed in 2023, and this year, there would be a final review of the 182 patients who died since January 2019.
Dame Clare Gerada emphasised the need for prompt action against Dr. Y. The review, described as comprehensive by Dr. Noon, aims to leave no stone unturned. The recent report also highlighted concerns about pharmaceutical costs, with some medicines priced at £1,000 per dose, raising accountability questions.
Chris Bown, chief officer of the Health department, acknowledged the unacceptability of patient harm and disclosed £1.3m spent on managing the review in 2023, indicating discussions about appropriate compensation with lawyers.